Biomarker test for bacterial infection in newborns
Part of Genetic & congenital, Infections clinical trials.
This trial tests a new biomarker (T6A) to detect bacterial infections in newborn babies. It aims to help doctors diagnose infections faster and more accurately.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a newborn baby needing blood tests for possible bacterial infection
- Your doctor thinks you might have a bacterial infection
- Your parents or caregivers give written permission for you to join
- You are not currently receiving any antibiotic treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at early signs of infection in premature babies. It checks two substances in the baby's blood (IL-6 and PCT) within the first 12 hours after birth to see if they can help detect sepsis early. Participation involves collecting a small extra blood sample during routine tests.
This trial tests a new, faster way to find bacteria in the blood of children with suspected sepsis. It uses a molecular test that may give results sooner than standard cultures, helping doctors treat infections more quickly.
This study looks at how blood markers like lactate and complete blood count (CBC) can help spot infection in newborns up to 28 days old. It may lead to faster, more accurate diagnosis for babies with possible sepsis.
This trial is testing whether certain biomarkers (substances in your body) can help diagnose sepsis faster. Sepsis is a serious condition where your body has a severe response to an infection. The study will look at blood or other samples to see if these markers can quickly tell if you have sepsis, which could lead to faster treatment.
This trial is testing whether a new, highly sensitive blood test (droplet digital PCR) combined with genetic analysis can help doctors predict sepsis earlier in emergency room patients. This could lead to faster treatment and better outcomes.
This study tests a new blood test (Microbio InfectID-BSI) to see how well it detects bacteria and yeast in patients with a possible bloodstream infection. If you are already having a blood culture done, the study will collect extra blood samples at the same time to compare the new test's results.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.